There are no files associated with this item.
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.citation.endPage | 378 | - |
dc.citation.startPage | 367 | - |
dc.citation.title | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.volume | 349 | - |
dc.contributor.author | Jun, Heejin | - |
dc.contributor.author | Jang, Eunjung | - |
dc.contributor.author | Kim, Hansol | - |
dc.contributor.author | Yeo, Mirae | - |
dc.contributor.author | Park, Seong Guk | - |
dc.contributor.author | Lee, Jaehyeok | - |
dc.contributor.author | Shin, Kyeong Jin | - |
dc.contributor.author | Chae, Young Chan | - |
dc.contributor.author | Kang, Sebyung | - |
dc.contributor.author | Kim, Eunhee | - |
dc.date.accessioned | 2023-12-21T13:42:43Z | - |
dc.date.available | 2023-12-21T13:42:43Z | - |
dc.date.created | 2022-07-13 | - |
dc.date.issued | 2022-09 | - |
dc.description.abstract | The TNF-related apoptosis-inducing ligand (TRAIL) is a promising anticancer drug candidate because it selectively binds to the proapoptotic death receptors, which are frequently overexpressed in a wide range of cancer cells, subsequently inducing strong apoptosis in these cells. However, the therapeutic benefit of TRAIL has not been clearly proven, mainly because of its poor pharmacokinetic characteristics and frequent resistance to its application caused by the activation of a survival signal via the EGF/epidermal growth factor receptor (EGFR) signaling pathway. Here, a lumazine synthase protein cage nanoparticle isolated from Aquifex aeolicus (AaLS) was used as a multiple ligand-displaying nanoplatform to display polyvalently both TRAIL and EGFR binding affibody molecules (EGFRAfb) via a SpyTag/SpyCatcher protein-ligation system, to form AaLS/TRAIL/EGFRAfb. The dual-ligand-displaying AaLS/TRAIL/EGFRAfb exhibited a dramatically enhanced cytotoxicity on TRAIL-resistant and EGFR-overexpressing A431 cancer cells in vitro, effectively disrupting the EGF-mediated EGFR survival signaling pathway by blocking EGF/EGFR binding as well as strongly activating both the extrinsic and intrinsic apoptotic pathways synergistically. The AaLS/TRAIL/EGFRAfb selectively targeted A431 cancer cells in vitro and actively reached the tumor sites in vivo. The A431 tumor-bearing mice treated with AaLS/TRAIL/EGFRAfb exhibited a significant suppression of the tumor growth without any significant side effects. Collectively, these findings showed that the AaLS/TRAIL/EGFRAfb could be used as an effective protein-based therapeutic for treating EGFR-positive cancers, which are difficult to manage using mono-therapeutic approaches. | - |
dc.identifier.bibliographicCitation | JOURNAL OF CONTROLLED RELEASE, v.349, pp.367 - 378 | - |
dc.identifier.doi | 10.1016/j.jconrel.2022.07.004 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.scopusid | 2-s2.0-85134223026 | - |
dc.identifier.uri | https://scholarworks.unist.ac.kr/handle/201301/58876 | - |
dc.identifier.wosid | 000879596800005 | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | TRAIL & EGFR affibody dual-display on a protein nanoparticle synergistically suppresses tumor growth | - |
dc.type | Article | - |
dc.description.isOpenAccess | FALSE | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary;Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry;Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordAuthor | TRAIL | - |
dc.subject.keywordAuthor | EGFR affibody | - |
dc.subject.keywordAuthor | Dual-ligand display | - |
dc.subject.keywordAuthor | Protein ligation | - |
dc.subject.keywordAuthor | Lumazine synthase | - |
dc.subject.keywordPlus | APOPTOSIS-INDUCING LIGAND | - |
dc.subject.keywordPlus | FACTOR RECEPTOR EGFR | - |
dc.subject.keywordPlus | TARGETED DELIVERY | - |
dc.subject.keywordPlus | CELL-DEATH | - |
dc.subject.keywordPlus | SIGNAL-TRANSDUCTION | - |
dc.subject.keywordPlus | CAGE NANOPARTICLES | - |
dc.subject.keywordPlus | HIGH-AFFINITY | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | SURFACE | - |
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Tel : 052-217-1404 / Email : scholarworks@unist.ac.kr
Copyright (c) 2023 by UNIST LIBRARY. All rights reserved.
ScholarWorks@UNIST was established as an OAK Project for the National Library of Korea.